VolitionRx Presents Nu.Q Vet Cancer Test at AMAMS 2025 in Thailand

VolitionRx showcased its Nu.Q Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties through two presentations. The studies explored the test's efficacy in diagnosing Canine Chronic Enteropathy versus Gastrointestinal Lymphoma and its use as a biomarker for canine nasal tumors. Collaboration with FujiFilm Vet Systems suggests potential for wider adoption in the Asian market. The test offers a less invasive, yet reliable, diagnostic alternative for these clinical scenarios.

VolitionRx Limited (NYSE AMERICAN: VNRX), a multi-national epigenetics company, showcased its Nu.Q Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025) in Thailand through two significant presentations. The studies explored the test's efficacy in diagnosing Canine Chronic Enteropathy versus Gastrointestinal Lymphoma and its use as a biomarker for canine nasal tumors.

The first study, led by Dr. Masahiko Sato in collaboration with FujiFilm Vet Systems, focused on the test's ability to accurately differentiate between Canine Chronic Enteropathy and Gastrointestinal Lymphoma. This differentiation is crucial as it often involves invasive diagnostic procedures. The Nu.Q Vet Cancer Test offers a less invasive, yet reliable, diagnostic alternative. Dr. Sato, a key opinion leader in veterinary medicine, highlighted the value of the test as a diagnostic tool [1].

The second presentation examined the potential of the test as a biomarker for canine nasal tumors by evaluating plasma nucleosome concentrations. This innovative approach presents significant promise in the field of veterinary oncology, particularly in the early detection and treatment monitoring of nasal tumors in dogs. The involvement of key industry players and the promising results bolster confidence in the test's potential integration into standard veterinary practices [2].

Both presentations took place on June 5, 2025, at AMAMS 2025, reflecting Volition's commitment to advancing veterinary diagnostics and expanding its market presence in Asia. The collaboration with FujiFilm Vet Systems suggests potential for wider adoption in the Asian market.

References:
[1] https://finance.yahoo.com/news/volition-announces-two-oral-presentations-010000294.html
[2] https://www.gurufocus.com/news/2909366/volition-announces-two-oral-presentations-at-asian-meeting-of-animal-medicine-specialties-vnrx-stock-news